TherapeuticsMD: TherapeuticsMD Full Year 2024 Earnings: US$0.20 loss per share (vs US$0.74 loss in FY 2023)

TherapeuticsMD ( NASDAQ:TXMD ) Full Year 2024 Results Key Financial Results Net loss: US$2.31m (loss narrowed by 70% from FY 2023). US$0.20 loss per share (improved from US$0.74 loss in FY 2023). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period TherapeuticsMD shares are up 10% from a week ago. Risk Analysis We don't want to rain on the parade too much, but we did also find 3 warning signs for TherapeuticsMD (1 doesn't sit too well with us!) that you need to be mindful of. Valuation is complex, but we're here to simplify it. Discover if TherapeuticsMD might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. About NasdaqGS:TXMD TherapeuticsMD Operates as a pharmaceutical royalty company in the United States. Flawless balance sheet and fair value. Similar Companies NYSE:MRK Merck NYSE:PFE Pfizer Merck Pfizer Market Insights Community Narratives